DAX24.226 +0,8%ESt505.415 +0,4%Top 10 Crypto14,71 +2,2%Dow42.344 +1,8%Nas19.199 +2,5%Bitcoin96.177 ±0,0%Euro1,1304 -0,3%Öl64,46 +0,3%Gold3.303 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 BYD A0M4W9 Tesla A1CX3T HENSOLDT HAG000 Siemens Energy ENER6Y thyssenkrupp 750000 Lufthansa 823212 Bayer BAY001 Deutsche Bank 514000 Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX nach Hoch über 24.300 Punkten mit Rekordschluss -- US-Handel endet mit Gewinnen -- BofA warnt vor NVIDIA-Ausblick -- D-Wave-Manager verkaufen Aktien -- Tesla, Siemens Energy, Rheinmetall im Fokus
Top News
Diese Werte hat Investoren-Legende Jeremy Grantham im ersten Quartal 2025 im Depot Diese Werte hat Investoren-Legende Jeremy Grantham im ersten Quartal 2025 im Depot
BYD bringt günstige Elektro-Limousine auf den Markt - Kampfansage an Tesla? BYD bringt günstige Elektro-Limousine auf den Markt - Kampfansage an Tesla?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Regen BioPharma A Aktie

Handeln
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA14P3K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75886M2017

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRGBPP

Regen BioPharma A Aktien News

DatumMeistgelesen
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024
PR NewswireRegen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023
PR NewswireRegen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments
PR NewswireRegen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
PR NewswireRegen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
PR NewswireRegen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
PR NewswireRegen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly
PR NewswireRegen BioPharma, Inc. Receives First Phase of Confirmatory Study
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on October 5, 2023
PR NewswireStudies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on February 22, 2023
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
PR NewswireRegen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
PR NewswireRegen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023
PR NewswireRegen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
PR NewswireRegen BioPharma Appoints Two New Scientific Advisory Board Members
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022
PR NewswireRegen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
PR NewswireRegen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic
PR NewswireRegen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022
PR NewswireRegen BioPharma, Inc. Explores the CAR-T Therapeutic Space
PR NewswireRegen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy
PR NewswireRegen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
PR NewswireRegen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
PR NewswireRegen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
PR NewswireRegen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine
Wer­bung

Regen BioPharma A News

Regen BioPharma A News: auf dieser Seite finden Sie alle Regen BioPharma A News und Nachrichten zur Regen BioPharma A Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Regen BioPharma A News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Regen BioPharma A News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.